[No role for oral anticoagulants (target INR: 2.0-3.0) after transient ischaemic attack or cerebral infarction of arterial origin; the 'European/Australasian stroke prevention in reversible ischaemia trial' (ESPRIT)]
- PMID: 18361194
[No role for oral anticoagulants (target INR: 2.0-3.0) after transient ischaemic attack or cerebral infarction of arterial origin; the 'European/Australasian stroke prevention in reversible ischaemia trial' (ESPRIT)]
Abstract
Objective: The 'European/Australasian stroke prevention in reversible ischaemia trial' (ESPRIT) aimed to determine whether oral anticoagulation of moderate intensity (target international normalised ratio (INR): 2.0-3.0) is more effective than acetylsalicylic acid in preventing future vascular events in patients with transient ischaemic attack (TIA) or minor stroke of arterial origin.
Design: International, multicentre randomised clinical trial.
Method: Patients were randomised within 6 months of TIA or minor stroke of arterial origin to oral anticoagulants (target INR: 2.0-3.0; n = 536) or acetylsalicylic acid (30-325 mg daily; n = 532). The primary endpoint was a composite of vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complications. In a post hoc analysis, the efficacy of anticoagulants was compared with that of the combination of acetylsalicylic acid and dipyridamole (200 mg twice daily), a third arm of ESPRIT. Treatment was unblinded, but auditing of endpoints was blinded. Data were analysed on an intent-to-treat basis.
Results: The comparison of anticoagulants and acetylsalicylic acid was stopped prematurely because the combination of acetylsalicylic acid and dipyridamole was found to be more effective than acetylsalicylic acid alone. The mean duration of follow-up was 4.6 years (SD: 2.2). The mean INR was 2.57 (SD: 0.86; nearly 70% of the time within target range). The primary endpoint occurred in 99 patients (19%) in the anticoagulation group and 98 patients (18%) in the acetylsalicylic acid group (hazard ratio: 1.02; 95% CI: 0.77-1.35). The hazard ratio was 0.73 (95% CI: 0.52-1.01) for ischaemic events and 2.56 (95% CI: 1.48-4.43) for major bleeding complications. The hazard ratio for the primary outcome event comparing anticoagulants with the combination of acetylsalicylic acid and dipyridamole was 1.31 (95% CI: 0.98-1.75).
Conclusion: Oral anticoagulants (target INR: 2.0-3.0) were not more effective than acetylsalicylic acid in the secondary prevention of vascular events following TIA or minor stroke of arterial origin.
Republished from
-
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.Lancet Neurol. 2007 Feb;6(2):115-24. doi: 10.1016/S1474-4422(06)70685-8. Lancet Neurol. 2007. PMID: 17239798 Clinical Trial.
Comment in
-
[Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].Ned Tijdschr Geneeskd. 2008 Feb 23;152(8):423-5. Ned Tijdschr Geneeskd. 2008. PMID: 18361189 Dutch.
Similar articles
-
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.Lancet Neurol. 2007 Feb;6(2):115-24. doi: 10.1016/S1474-4422(06)70685-8. Lancet Neurol. 2007. PMID: 17239798 Clinical Trial.
-
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?].Ned Tijdschr Geneeskd. 1998 Feb 7;142(6):316-8. Ned Tijdschr Geneeskd. 1998. PMID: 9562733 Clinical Trial. Dutch.
-
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.Ann Neurol. 1997 Dec;42(6):857-65. doi: 10.1002/ana.410420606. Ann Neurol. 1997. PMID: 9403477 Clinical Trial.
-
Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.Curr Med Res Opin. 2007 Jun;23(6):1453-62. doi: 10.1185/030079907X199727. Epub 2007 May 17. Curr Med Res Opin. 2007. PMID: 17559741 Review.
-
Anticoagulant treatment in stroke prevention.Rev Neurol (Paris). 1999;155(9):694-6. Rev Neurol (Paris). 1999. PMID: 10528351 Review.
Cited by
-
Hydroxybutyrate promotes the recovery from cerebral infarction by activating Amp-activated protein kinase signaling.Exp Ther Med. 2018 Aug;16(2):1195-1202. doi: 10.3892/etm.2018.6304. Epub 2018 Jun 13. Exp Ther Med. 2018. PMID: 30116369 Free PMC article.